Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyproterone acetate added to quetiapine for agitation and aggression in Alzheimer's dementia
IRCT20220109053673N1Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cyproterone and quetiapine in Alzheimer's disease (AD) and Dementia, sponsored by University of Social Welfare and Rehabilitation Sciences. Started May 2025; status: completed.
02
Drugs
cyproteronequetiapine
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on IRCT20220109053673N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220109053673N1.